Amgen Inc. (AMGN)

251.53
1.60 0.64
NASDAQ : Health Technology
Prev Close 253.15
Open 253.15
Day Low/High 249.25 / 253.97
52 Wk Low/High 173.12 / 264.97
Volume 1.96M
Avg Volume 2.87M
Exchange NASDAQ
Shares Outstanding 588.25M
Market Cap 150.74B
EPS 13.00
P/E Ratio 20.07
Div & Yield 6.40 (2.36%)

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...

Closing Bell: Casino Stocks Climb on Japan's Gambling Bill; Records For Wall Street

Closing Bell: Casino Stocks Climb on Japan's Gambling Bill; Records For Wall Street

Wall Street scores another trifecta of record closes as a rally in the energy and tech sectors drive gains across benchmark indexes.

Amgen Charts Don't Generate Much Enthusiasm

Amgen Charts Don't Generate Much Enthusiasm

The biotech probably needs a period of sideways price action before a new rally to the upper end of the trading range gets underway.

I'm Buying Biotech on This Trump Scare

I'm Buying Biotech on This Trump Scare

If the market is going to overreact to every new missive from Trump, I plan to take advantage.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

How to Play Rising Treasury Yields

How to Play Rising Treasury Yields

Check out these 15 stocks that boast solid dividend yields and are growing earnings.

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.

Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing

Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing

I continue to believe downside risks far outweigh the risks of a near-term rally.

You Should Be Your Own Harshest Critic

You Should Be Your Own Harshest Critic

tk

In a Deteriorating Market, Shorten Your Timeframe

In a Deteriorating Market, Shorten Your Timeframe

We may see a respite of the recent pressure for a few days, but it can't be trusted to last.

Amgen: Indicators Are Mixed, What Could Be Next?

Amgen: Indicators Are Mixed, What Could Be Next?

AMGN is neutral now, but a close below $158 weakens the chart picture.

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

Closing Bell: Wells Fargo Considers Clawbacks; U.S. Stocks Climb

Closing Bell: Wells Fargo Considers Clawbacks; U.S. Stocks Climb

U.S. stocks climbed and the Dow Jones Industrial Average jumped more than 100 points thanks to gains in the tech and consumer sectors.

Gilead: Horse of a Different, uh, Color

Gilead: Horse of a Different, uh, Color

The once-mighty biotech has fallen, but entry opportunities will surface.

Is Amgen the Cure for the Market Blues?

Is Amgen the Cure for the Market Blues?

The shares have some power and legs to get up and through old highs.

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

Charts Show Something Broke Friday

Charts Show Something Broke Friday

Often, pictures speak louder than words.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Stocks secure robust gains after the latest labor market snapshot breezes past expectations.

Housing, Biotech Offer Affordable Growth

Housing, Biotech Offer Affordable Growth

These sectors offer value as the S&P 500 trades at 19x earnings.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Can Amgen Break Out?

Can Amgen Break Out?

The company has pushed to the top of a large consolidation pattern.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Amgen estimates, target increased at BMO